Stealth’s Elamipretide Efficacy In Barth Syndrome Not Shown, US FDA Says

 
• By Sue Sutter
  
Climbing steep hill
Stealth faces a steep hill at the FDA cardio-renal adcomm on elamipretide. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from US Advisory Committees